Why is the use of digitalis withering? Another reason that we need medical heart failure specialists

European Journal of Heart Failure

Volumn 20, Issue 5, 2018, Pages 851-852

  Packer, Milton ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGITALIS; CARDIOTONIC AGENT; DIGITALIS GLYCOSIDE;

CARDIOLOGIST; CARDIOVASCULAR MORTALITY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEART FAILURE; HUMAN; MORTALITY RISK; NOTE; PATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; CLINICAL COMPETENCE; STANDARDS;

CARDIOLOGISTS; CARDIOTONIC AGENTS; CLINICAL COMPETENCE; DIGITALIS GLYCOSIDES; HEART FAILURE; HUMANS;

EID: 85031727996     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.1043     Document Type: Note

References (15)

1. Lee MR (2005). William Withering (1741–1799), a biographical sketch of a Birmingham lunatic. JLL Bulletin: Commentaries on the history of treatment evaluation. Available at: http://www.jameslindlibrary.org/articles/william-withering-1741--1799-a-biographical-sketch-of-a-birmingham-lunatic (13 October 2017).
2. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–533.
3. Patel N, Ju C, Macon C, Thadani U, Schulte PJ, Hernandez AF, Bhatt DL, Butler J, Yancy CW, Fonarow GC. Temporal trends of digoxin use in patients hospitalized with heart failure: analysis from the American Heart Association Get With the Guidelines-Heart Failure Registry. JACC Heart Fail 2016;4:348–356.
4. Packer M. Unbelievable folly of clinical trials in heart failure: the inconvenient truth about How investigators and guidelines weigh evidence. Circ Heart Fail 2016;9:e002837.
5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
6. Adams KF Jr, Butler J, Patterson JH, Gattis Stough W, Bauman JL, van Veldhuisen DJ, Schwartz TA, Sabbah H, Mackowiak JI, Ventura HO, Ghali JK. Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. Eur J Heart Fail 2016;18:1072–1081.
7. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403–1411.
8. Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes 2013;6:525–533.
9. Ahmed A, Bourge RC, Fonarow GC, Patel K, Morgan CJ, Fleg JL, Aban IB, Love TE, Yancy CW, Deedwania P, van Veldhuisen DJ, Filippatos GS, Anker SD, Allman RM. Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure. Am J Med 2014;127:61–70.
10. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JG, Dargie HJ, Granger CB, Kjekshus J, Køber L, Latini R, Maggioni AP, Packer M, Pitt B, Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad F, Zile MR, McMurray JJ. Declining risk of sudden death in heart failure. N Engl J Med 2017;377:41–51.
11. Raebel MA, Carroll NM, Andrade SE, Chester EA, Lafata JE, Feldstein A, Gunter MJ, Nelson WW, Simon SR, Chan KA, Davis RL, Platt R. Monitoring of drugs with a narrow therapeutic range in ambulatory care. Am J Manag Care 2006;12:268–274.
12. Ambrosy AP, Gheorghiade M. Targeting digoxin dosing to serum concentration: is the bullseye too small? Eur J Heart Fail 2016;18:1082–1084.
13. Packer M. How have millions of people with heart failure benefited from our research over the last 10–15 years? The sounds of dead silence. Eur J Heart Fail 2017;19:1353–1354.
14. Packer M. Who should deliver medical therapy for patients with chronic heart failure? An immediate call for action to implement a community-based collaborative solution. Circ Heart Fail 2017;10:e004332.
15. Packer M. Angiotensin neprilysin inhibition for patients with heart failure: what if sacubitril/valsartan were a treatment for cancer? JAMA Cardiol 2016;1:971–972.